PMID- 38243958
OWN - NLM
STAT- Publisher
LR  - 20240120
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
DP  - 2024 Jan 11
TI  - Use of Network Pharmacology and Experiment Validation to Uncover the Mechanism of 
      Jianshen Lishui Prescription in the Treatment of Intracerebral Hemorrhage.
LID - 10.2174/0113862073256436231031100059 [doi]
AB  - BACKGROUND: As a Chinese medicinal formula, the Jianshen Lishui prescription has 
      been clinically proven to be effective in treating intracerebral hemorrhage 
      (ICH). Yet, the mechanisms involved are unknown. METHODS: (1) Network 
      pharmacology analysis: It involved the screening of active components in the 
      Jianshen Lishui prescription, identification of potential targets for these 
      components, and the screening of ICH-related targets. Common targets for both 
      disease and drug were identified. Protein- protein interaction networks were 
      constructed, followed by further screening of core targets. Gene Ontology(GO) 
      enrichment analysis and Kyoto Encyclopedia of Genes and Genomes( KEGG) pathway 
      enrichment analysis were performed on these core targets. Finally, molecular 
      docking verification was carried out using the active components and core 
      targets. (2) Experimental verification: It was conducted using a rat model of 
      intracerebral hemorrhage. This involved observing neurological deficit scores in 
      the rats and measuring cerebral water content. The effects of Jianshen Lishui 
      prescription on the neurological function, cerebral water content, and brain 
      tissue core targets were observed through HE staining, Western blot and qPCR. 
      RESULTS: (1) In this study, 29 common targets were obtained by intersecting 256 
      potential drug targets and 642 genes associated with ICH. 9 core targets were 
      obtained by employing the protein- protein interaction (PPI) construction system 
      to screen more specific targets. In addition, the findings revealed that the 
      molecular mechanism of Jianshen Lishui prescription in treating ICH was mainly 
      related to cancer signaling pathways and signal transduction pathways, based on 
      the results of GO and KEGG enrichment analysis. Molecular docking results showed 
      that the active constituent of Jianshen Lishui prescription mannitol has the 
      highest binding activity with KRAS, luteolin, and Poria sterol with AR, INS1 and 
      KRAS, cerebrosterol with GNB1, INS and ESR1, and sitosterol with AR, INS1 and 
      KRAS. (2) Animal experiments verified that Jianshen Lishui prescription 
      significantly alleviated encephaledema and improved nerve functions of the rat 
      model of ICH. And INS1 expression levels were upregulated and the expression 
      levels of AR, KRAS, PTGS2, and ESR1 were down-regulated by the prescription. 
      CONCLUSION: Jianshen Lishui prescription protects the nerve function of ICH 
      patients by inhibiting inflammation and reducing cerebral edema. This study 
      provides more supportive evidences for the clinical use of traditional Chinese 
      prescriptions in ICH treatment.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Yuguang, Gao
AU  - Yuguang G
AUID- ORCID: 0000-0003-1704-6235
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Deqing, Huang
AU  - Deqing H
AUID- ORCID: 0000-0001-7763-0359
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Jie, Zhong
AU  - Jie Z
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Yujuan, Ma
AU  - Yujuan M
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Kan, Yang
AU  - Kan Y
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Yuxiong, Liao
AU  - Yuxiong L
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
FAU - Qiong, Zhu
AU  - Qiong Z
AD  - Guangxi University of Chinese Medicine, China.
FAU - Qiqi, Liu
AU  - Qiqi L
AD  - Neurology Department of the First Affiliated Hospital of Guangxi University of 
      Chinese Medicine, China.
LA  - eng
PT  - Journal Article
DEP - 20240111
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
SB  - IM
OTO - NOTNLM
OT  - Jianshen lishui prescription
OT  - experimental evaluation.
OT  - intracerebral hemorrhage
OT  - mechanism of action
OT  - molecular docking
OT  - network pharmacology
EDAT- 2024/01/20 21:41
MHDA- 2024/01/20 21:41
CRDT- 2024/01/20 10:14
PHST- 2023/06/13 00:00 [received]
PHST- 2023/09/19 00:00 [revised]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2024/01/20 21:41 [medline]
PHST- 2024/01/20 21:41 [pubmed]
PHST- 2024/01/20 10:14 [entrez]
AID - CCHTS-EPUB-137257 [pii]
AID - 10.2174/0113862073256436231031100059 [doi]
PST - aheadofprint
SO  - Comb Chem High Throughput Screen. 2024 Jan 11. doi: 
      10.2174/0113862073256436231031100059.